News / Korea / yonhap_finance
Alteogen Shares Surge on $3.2 Billion Licensing Deal with Novartis
Health Technology · Biotechnology · yonhap_finance · 2026-09-03
196170
Alteogen's stock rose after announcing a major licensing agreement with Novartis for its proprietary subcutaneous injection technology platform, ALT-B4.
What Happened
Major Licensing Deal: Alteogen has signed a significant licensing and option agreement with global pharmaceutical giant Novartis for its proprietary subcutaneous (SC) injection technology platform, ALT-B4. This deal marks a major milestone for the company in the global biopharmaceutical market.
Financial Terms: Under the terms of the agreement, Alteogen stands to receive up to $3.223 billion (approximately 4.4 trillion KRW) if all options are exercised and development and commercialization milestones are met. This represents a substantial financial boost for the company's long-term growth strategy.
Technology Overview: ALT-B4 is a recombinant human hyaluronidase developed using Alteogen's proprietary 'Hybrozyme' platform. The technology allows for the conversion of intravenous drugs into subcutaneous injections, significantly improving patient convenience and treatment accessibility.
Market Impact: Following the announcement, Alteogen's shares experienced a strong rally during early trading hours. Investors have reacted positively to the deal, viewing it as a validation of the company's technological competitiveness and its potential to secure further global partnerships.